|
시장보고서
상품코드
1860012
세계의 광선각화증 치료 : 시장 점유율과 순위, 전체 판매량 및 수요 예측(2025-2031년)Actinic Keratosis Treatment - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031 |
||||||
QYResearch
광선각화증 치료 시장 규모는 2024년에 87억 6,400만 달러로 평가되었고, 2025-2031년의 예측 기간에 CAGR 6.1%로 성장하여 2031년까지 131억 4,400만 달러에 이를 것으로 예측됩니다.
광선각화증(AKs 또는 일광각화증)은 장기간의 자외선 노출에 반응하여 이형 각질세포의 표피 내 증식이 일어나면서 발생하는 각화반, 구진, 또는 플라크입니다. 가장 흔하게 나타나는 부위는 얼굴, 입술, 귀, 손등, 팔뚝, 두피, 목 등입니다.
수요 측면에서 AK 치료는 여러 가지 성장 요인에 의해 뒷받침되고 있습니다. 고령화와 자외선 노출과 관련된 생활습관으로 인해 잠재적 환자군이 확대되고, 조기 발견과 피부암 예방에 대한 공중보건의 중요성이 높아지면서 표준화된 진단 및 현장 치료 접근법의 도입이 촉진되고 있습니다. 기술 혁신과 제형 개발(개선된 외용제 기제, 새로운 광역학 치료(PDT) 캐리어, 보다 편리한 투여 형태)과 더불어 디지털 피부과 진료 채널의 보급으로 기업들은 제품 라인을 확장하고 시장 침투를 심화시킬 수 있는 기회를 얻었습니다. 각 회사의 연례 보고서에서 PDT와 혁신적인 외용제 처방약에 대한 상업적 집중을 차별화 전략으로 강조하고 있습니다.
분명한 기회가 있는 반면, 뚜렷한 위험도 존재한다: 많은 치료가 병변 부위에 집중되어 있어 국소 자극을 유발할 수 있고, 환자의 수용성과 치료 지속성을 떨어뜨릴 수 있습니다. 신약-신기기 개발에는 장기간의 시험 기간, 높은 연구개발비용, 규제 측면의 불확실성이 수반됩니다. 시장마다 상환 프레임워크와 기기 승인 프로세스가 크게 달라 고부가가치 치료법의 도입을 방해할 수 있습니다. 규제 투명성과 실제 임상 데이터(RWE)를 유지하지 못하면 기업은 규제 당국의 감시 대상이 되어 시장의 신뢰를 잃을 수 있습니다.
수요는 통합형 '치료+유지' 모델로 전환되고 있으며, 저자극적이고 복약순응도가 높은 병용요법이 강조되는 추세입니다. 이에 따라 의료기기와 처방약의 연계 강화, 시판 스킨케어 제품과 처방 채널의 융합이 진행되고 있습니다. 업스트림 공정의 주요 투입물로는 외용제 및 전신용 의약품의 유효성분(API), 광증감제 및 광역학 치료(PDT)용 약물 운반체, 레이저/광치료기용 광학 및 전자부품 등이 있습니다. 단일 라인의 생산 능력 측면에서 특정 감광제 및 저분자 API의 합성 경로는 특수 중간체 및 촉매에 의존하고 있으며, 생산 능력 확대에는 긴 리드 타임이 필요합니다. 고급 광학 부품은 소수공급업체에 집중되어 있어 리드 타임과 품질 관리의 병목 현상이 발생하고 있습니다. 천연 추출물과 보조 성분은 스케일업과 표준화 문제에 직면해 있습니다. 업스트림 공정에 대한 투자가 미흡할 경우, 수요 급증이나 규제 변경 시 공급 부족 및 비용 변동 위험이 발생합니다.
이 보고서는 광선각화증 치료제 세계 시장에 대해 총 매출액, 주요 기업의 시장 점유율 및 순위에 초점을 맞추어 지역별, 국가별, 유형별, 용도별 분석을 종합적으로 제시하는 것을 목적으로 합니다.
광선각화증 치료제 시장 규모, 추정 및 예측은 2024년을 기준 연도로 하여 2020년에서 2031년까지의 기간의 과거 데이터와 예측 데이터를 포함하는 매출액으로 제시되어 있습니다. 정량적 분석과 정성적 분석을 통해 독자들이 광선각화증 치료제와 관련된 비즈니스/성장 전략을 수립하고, 시장 경쟁을 평가하고, 현재 시장에서의 포지셔닝을 분석하고, 정보에 입각한 비즈니스 의사결정을 내릴 수 있도록 돕습니다.
시장 세분화
기업별
- DUSA Pharmaceuticals
- Novartis
- Perrigo
- LEO Pharma
- Bausch Health
- Taro Pharmaceutical
- Galderma(Nestle)
- Biofrontera
- Almirall
- Tolmar Pharmaceutical
- Biofrontera
- Novartis
- Sun Pharmaceutical
- Photocure ASA
유형별 부문
- 파괴적 치료
- 광역동 치료
- 외용약
- 기타
용도별 부문
- 병원
- 클리닉
- 기타
지역별
- 북미
- 미국
- 캐나다
- 아시아태평양
- 중국
- 일본
- 한국
- 동남아시아
- 인도
- 호주
- 기타 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 네덜란드
- 북유럽 국가
- 기타 유럽
- 라틴아메리카
- 멕시코
- 브라질
- 기타 라틴아메리카
- 중동 및 아프리카
- 튀르키예
- 사우디아라비아
- 아랍에미리트(UAE)
- 기타 중동 및 아프리카
자주 묻는 질문
The global market for Actinic Keratosis Treatment was estimated to be worth US$ 8764 million in 2024 and is forecast to a readjusted size of US$ 13144 million by 2031 with a CAGR of 6.1% during the forecast period 2025-2031.
Actinic keratosis (AKs or solar keratoses) are keratotic macules, papules, or plaques resulting from the intraepidermal proliferation of atypical keratinocytes in response to prolonged exposure to ultraviolet radiation. It's most commonly found on the face, lips, ears, back of your hands, forearms, scalp or neck.
On the demand side, AK treatment is supported by multiple growth drivers: aging populations and UV-exposure related lifestyles expand the potential patient pool; increased public health emphasis on early detection and skin-cancer prevention encourages adoption of standardized diagnostic and field-treatment approaches. Technological and formulation innovations (improved topical vehicles, novel PDT carriers, and more convenient delivery formats), together with digital dermatology channels, provide firms opportunities for product line extension and deeper market penetration. Company annual reports highlight commercial focus on PDT and innovative topical prescriptions as a differentiation strategy.
Despite clear opportunities, notable risks exist: many treatments are lesion-focused and can cause local irritation that reduces patient acceptance and follow-up; development of new drugs and devices entails long trial timelines, high R&D costs, and regulatory uncertainty; reimbursement frameworks and device approval pathways vary widely by market and may impede adoption of premium therapies. Failure to maintain regulatory transparency and real-world evidence can expose companies to regulatory scrutiny and erode market trust.
Demand is shifting toward an integrated "treat + maintain" model, favoring low-irritation, high-adherence combination regimens, with stronger linkages between devices and prescription drugs and convergence of OTC skincare with prescription channels. Upstream key inputs include APIs for topical/systemic agents, photosensitizers and PDT pharmaceutical carriers, and optical/electronic components for laser/light devices. From a single-line capacity perspective, synthesis routes for certain photosensitizers and small-molecule APIs depend on specialized intermediates and catalysts, requiring lengthy capacity expansion lead times; high-end optical components are concentrated among a few suppliers, creating lead-time and quality control bottlenecks; natural extracts and adjunctive ingredients face scalability and standardization issues. Insufficient upstream investment risks supply shortages and cost volatility when demand spikes or regulations change.
This report aims to provide a comprehensive presentation of the global market for Actinic Keratosis Treatment, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Actinic Keratosis Treatment by region & country, by Type, and by Application.
The Actinic Keratosis Treatment market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Actinic Keratosis Treatment.
Market Segmentation
By Company
- DUSA Pharmaceuticals
- Novartis
- Perrigo
- LEO Pharma
- Bausch Health
- Taro Pharmaceutical
- Galderma (Nestle)
- Biofrontera
- Almirall
- Tolmar Pharmaceutical
- Biofrontera
- Novartis
- Sun Pharmaceutical
- Photocure ASA
Segment by Type
- Destructive Treatment
- Photodynamic Therapy
- Topical Medications
- Others
Segment by Application
- Hospital
- Clinic
- Others
By Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Actinic Keratosis Treatment company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Actinic Keratosis Treatment in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Actinic Keratosis Treatment in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Table of Contents
1 Market Overview
- 1.1 Actinic Keratosis Treatment Product Introduction
- 1.2 Global Actinic Keratosis Treatment Market Size Forecast (2020-2031)
- 1.3 Actinic Keratosis Treatment Market Trends & Drivers
- 1.3.1 Actinic Keratosis Treatment Industry Trends
- 1.3.2 Actinic Keratosis Treatment Market Drivers & Opportunity
- 1.3.3 Actinic Keratosis Treatment Market Challenges
- 1.3.4 Actinic Keratosis Treatment Market Restraints
- 1.4 Assumptions and Limitations
- 1.5 Study Objectives
- 1.6 Years Considered
2 Competitive Analysis by Company
- 2.1 Global Actinic Keratosis Treatment Players Revenue Ranking (2024)
- 2.2 Global Actinic Keratosis Treatment Revenue by Company (2020-2025)
- 2.3 Key Companies Actinic Keratosis Treatment Manufacturing Base Distribution and Headquarters
- 2.4 Key Companies Actinic Keratosis Treatment Product Offered
- 2.5 Key Companies Time to Begin Mass Production of Actinic Keratosis Treatment
- 2.6 Actinic Keratosis Treatment Market Competitive Analysis
- 2.6.1 Actinic Keratosis Treatment Market Concentration Rate (2020-2025)
- 2.6.2 Global 5 and 10 Largest Companies by Actinic Keratosis Treatment Revenue in 2024
- 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Actinic Keratosis Treatment as of 2024)
- 2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
- 3.1 Introduction by Type
- 3.1.1 Destructive Treatment
- 3.1.2 Photodynamic Therapy
- 3.1.3 Topical Medications
- 3.1.4 Others
- 3.2 Global Actinic Keratosis Treatment Sales Value by Type
- 3.2.1 Global Actinic Keratosis Treatment Sales Value by Type (2020 VS 2024 VS 2031)
- 3.2.2 Global Actinic Keratosis Treatment Sales Value, by Type (2020-2031)
- 3.2.3 Global Actinic Keratosis Treatment Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
- 4.1 Introduction by Application
- 4.1.1 Hospital
- 4.1.2 Clinic
- 4.1.3 Others
- 4.2 Global Actinic Keratosis Treatment Sales Value by Application
- 4.2.1 Global Actinic Keratosis Treatment Sales Value by Application (2020 VS 2024 VS 2031)
- 4.2.2 Global Actinic Keratosis Treatment Sales Value, by Application (2020-2031)
- 4.2.3 Global Actinic Keratosis Treatment Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
- 5.1 Global Actinic Keratosis Treatment Sales Value by Region
- 5.1.1 Global Actinic Keratosis Treatment Sales Value by Region: 2020 VS 2024 VS 2031
- 5.1.2 Global Actinic Keratosis Treatment Sales Value by Region (2020-2025)
- 5.1.3 Global Actinic Keratosis Treatment Sales Value by Region (2026-2031)
- 5.1.4 Global Actinic Keratosis Treatment Sales Value by Region (%), (2020-2031)
- 5.2 North America
- 5.2.1 North America Actinic Keratosis Treatment Sales Value, 2020-2031
- 5.2.2 North America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
- 5.3 Europe
- 5.3.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031
- 5.3.2 Europe Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
- 5.4 Asia Pacific
- 5.4.1 Asia Pacific Actinic Keratosis Treatment Sales Value, 2020-2031
- 5.4.2 Asia Pacific Actinic Keratosis Treatment Sales Value by Region (%), 2024 VS 2031
- 5.5 South America
- 5.5.1 South America Actinic Keratosis Treatment Sales Value, 2020-2031
- 5.5.2 South America Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
- 5.6 Middle East & Africa
- 5.6.1 Middle East & Africa Actinic Keratosis Treatment Sales Value, 2020-2031
- 5.6.2 Middle East & Africa Actinic Keratosis Treatment Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
- 6.1 Key Countries/Regions Actinic Keratosis Treatment Sales Value Growth Trends, 2020 VS 2024 VS 2031
- 6.2 Key Countries/Regions Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.3 United States
- 6.3.1 United States Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.3.2 United States Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.3.3 United States Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.4.2 Europe Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.4.3 Europe Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.5 China
- 6.5.1 China Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.5.2 China Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.5.3 China Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.6 Japan
- 6.6.1 Japan Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.6.2 Japan Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.6.3 Japan Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.7 South Korea
- 6.7.1 South Korea Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.7.2 South Korea Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.7.3 South Korea Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.8 Southeast Asia
- 6.8.1 Southeast Asia Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.8.2 Southeast Asia Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.8.3 Southeast Asia Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
- 6.9 India
- 6.9.1 India Actinic Keratosis Treatment Sales Value, 2020-2031
- 6.9.2 India Actinic Keratosis Treatment Sales Value by Type (%), 2024 VS 2031
- 6.9.3 India Actinic Keratosis Treatment Sales Value by Application, 2024 VS 2031
7 Company Profiles
- 7.1 DUSA Pharmaceuticals
- 7.1.1 DUSA Pharmaceuticals Profile
- 7.1.2 DUSA Pharmaceuticals Main Business
- 7.1.3 DUSA Pharmaceuticals Actinic Keratosis Treatment Products, Services and Solutions
- 7.1.4 DUSA Pharmaceuticals Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.1.5 DUSA Pharmaceuticals Recent Developments
- 7.2 Novartis
- 7.2.1 Novartis Profile
- 7.2.2 Novartis Main Business
- 7.2.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions
- 7.2.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.2.5 Novartis Recent Developments
- 7.3 Perrigo
- 7.3.1 Perrigo Profile
- 7.3.2 Perrigo Main Business
- 7.3.3 Perrigo Actinic Keratosis Treatment Products, Services and Solutions
- 7.3.4 Perrigo Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.3.5 Perrigo Recent Developments
- 7.4 LEO Pharma
- 7.4.1 LEO Pharma Profile
- 7.4.2 LEO Pharma Main Business
- 7.4.3 LEO Pharma Actinic Keratosis Treatment Products, Services and Solutions
- 7.4.4 LEO Pharma Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.4.5 LEO Pharma Recent Developments
- 7.5 Bausch Health
- 7.5.1 Bausch Health Profile
- 7.5.2 Bausch Health Main Business
- 7.5.3 Bausch Health Actinic Keratosis Treatment Products, Services and Solutions
- 7.5.4 Bausch Health Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.5.5 Bausch Health Recent Developments
- 7.6 Taro Pharmaceutical
- 7.6.1 Taro Pharmaceutical Profile
- 7.6.2 Taro Pharmaceutical Main Business
- 7.6.3 Taro Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
- 7.6.4 Taro Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.6.5 Taro Pharmaceutical Recent Developments
- 7.7 Galderma (Nestle)
- 7.7.1 Galderma (Nestle) Profile
- 7.7.2 Galderma (Nestle) Main Business
- 7.7.3 Galderma (Nestle) Actinic Keratosis Treatment Products, Services and Solutions
- 7.7.4 Galderma (Nestle) Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.7.5 Galderma (Nestle) Recent Developments
- 7.8 Biofrontera
- 7.8.1 Biofrontera Profile
- 7.8.2 Biofrontera Main Business
- 7.8.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
- 7.8.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.8.5 Biofrontera Recent Developments
- 7.9 Almirall
- 7.9.1 Almirall Profile
- 7.9.2 Almirall Main Business
- 7.9.3 Almirall Actinic Keratosis Treatment Products, Services and Solutions
- 7.9.4 Almirall Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.9.5 Almirall Recent Developments
- 7.10 Tolmar Pharmaceutical
- 7.10.1 Tolmar Pharmaceutical Profile
- 7.10.2 Tolmar Pharmaceutical Main Business
- 7.10.3 Tolmar Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
- 7.10.4 Tolmar Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.10.5 Tolmar Pharmaceutical Recent Developments
- 7.11 Biofrontera
- 7.11.1 Biofrontera Profile
- 7.11.2 Biofrontera Main Business
- 7.11.3 Biofrontera Actinic Keratosis Treatment Products, Services and Solutions
- 7.11.4 Biofrontera Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.11.5 Biofrontera Recent Developments
- 7.12 Novartis
- 7.12.1 Novartis Profile
- 7.12.2 Novartis Main Business
- 7.12.3 Novartis Actinic Keratosis Treatment Products, Services and Solutions
- 7.12.4 Novartis Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.12.5 Novartis Recent Developments
- 7.13 Sun Pharmaceutical
- 7.13.1 Sun Pharmaceutical Profile
- 7.13.2 Sun Pharmaceutical Main Business
- 7.13.3 Sun Pharmaceutical Actinic Keratosis Treatment Products, Services and Solutions
- 7.13.4 Sun Pharmaceutical Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.13.5 Sun Pharmaceutical Recent Developments
- 7.14 Photocure ASA
- 7.14.1 Photocure ASA Profile
- 7.14.2 Photocure ASA Main Business
- 7.14.3 Photocure ASA Actinic Keratosis Treatment Products, Services and Solutions
- 7.14.4 Photocure ASA Actinic Keratosis Treatment Revenue (US$ Million) & (2020-2025)
- 7.14.5 Photocure ASA Recent Developments
8 Industry Chain Analysis
- 8.1 Actinic Keratosis Treatment Industrial Chain
- 8.2 Actinic Keratosis Treatment Upstream Analysis
- 8.2.1 Key Raw Materials
- 8.2.2 Raw Materials Key Suppliers
- 8.2.3 Manufacturing Cost Structure
- 8.3 Midstream Analysis
- 8.4 Downstream Analysis (Customers Analysis)
- 8.5 Sales Model and Sales Channels
- 8.5.1 Actinic Keratosis Treatment Sales Model
- 8.5.2 Sales Channel
- 8.5.3 Actinic Keratosis Treatment Distributors
9 Research Findings and Conclusion
10 Appendix
- 10.1 Research Methodology
- 10.1.1 Methodology/Research Approach
- 10.1.1.1 Research Programs/Design
- 10.1.1.2 Market Size Estimation
- 10.1.1.3 Market Breakdown and Data Triangulation
- 10.1.2 Data Source
- 10.1.2.1 Secondary Sources
- 10.1.2.2 Primary Sources
- 10.1.1 Methodology/Research Approach
- 10.2 Author Details
- 10.3 Disclaimer
